Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis
Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis
复制标题
DOI：
10.1007/s10072-003-0180-5
复制
发表时间：
2003-12-01
影响因子：
3.3
通讯作者：
Millefiorini, E
中科院分区：
文献类型：
--
作者：
Bagnato, F;Durastanti, V;Millefiorini, E
多发性硬化症(MS)是一种主要由T辅助细胞1介导的中枢神经系统自身免疫性疾病。磁共振成像(MRI)是监测疾病活动和进展的最有用的工具。然而，核磁共振是一项昂贵且耗时的测试。因此，能够测量体液中与MRI疾病活动相关的生物标志物是非常重要的。在一些自身免疫性疾病中，β-2微球蛋白(β2-MG)和新喋呤被发现与疾病活动有关，并被用作干扰素β治疗MS的药效学标志物。在MS的自然病程中，β2-MG随时间稳定，因此监测其血浆水平不太可能成为疾病变化的有用标志物。临床复发时尿中新喋呤的排泄量较高，但血液中该分子的水平与临床和MRI测量结果无关。
Multiple sclerosis (MS) is a predominately T helper 1-mediated autoimmune disease of the central nervous system. Magnetic resonance imaging (MRI) is the most useful tool for monitoring disease activity and progression. However, MRI is an expensive and time-consuming test. Therefore, the ability to measure biological markers in body fluids correlating with MRI disease activity is of great importance. Beta-2 microglobulin (beta2-MG) and neopterin have been found to correlate with disease activity in several autoimmune disorders and are used as pharmacodynamic markers of interferon beta treatment in MS. During the natural course of MS, beta2-MG is stable over time, and thus it is unlikely that monitoring its plasma levels will be a useful marker of disease changes. More controversial results have been found for neopterin evaluations in MS. Urinary excretion of neopterin is higher during a clinical relapse but blood levels of this molecule do not correlate with clinical and MRI measurements.